Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial

BACKGROUND: From early in the COVID-19 pandemic, evidence suggested a role for cytokine dysregulation and complement activation in severe disease. In the TACTIC-R trial, we evaluated the efficacy and safety of baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, and ravulizumab, a monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Frances C, Cheriyan, Joseph, Cope, Andrew P, Galloway, James, Wilkinson, Ian, Bond, Simon, Norton, Sam, Banham-Hall, Edward, Bayes, Hannah, Kostapanos, Michalis, Nodale, Marianna, Petchey, William G, Sheeran, Thomas, Underwood, Jonathan, Jayne, David R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682367/
https://www.ncbi.nlm.nih.gov/pubmed/37977159
http://dx.doi.org/10.1016/S2213-2600(23)00376-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682367/
https://www.ncbi.nlm.nih.gov/pubmed/37977159
http://dx.doi.org/10.1016/S2213-2600(23)00376-4

Ejemplares similares